How Clorox Employees are Prioritizing Preventive Care

NORTHAMPTON, MA / ACCESSWIRE / May 15, 2024 / We put off routine screenings and sometimes even avoid them. But you never know when one might save your life.

That was the experience of Natalie Hovany, our vice president of HR business partnership, who went in for her regular mammogram despite having no symptoms, only to have the test uncover triple-negative breast cancer. Despite the difficult diagnosis, it allowed her doctors to treat the cancer at an early stage, increasing the likelihood of success.

As part of our ongoing commitment to our teammates' health and well-being, we put in place an educational campaign to increase use of preventive care screenings and track our progress against that goal. Over the last year, we've seen a significant increase in the number of teammates and their family members prioritizing preventive care by getting annual well visits, building a relationship with their primary care physician and scheduling routine screenings - all of which we expect to contribute to improved health outcomes.

Looking for inspiration to make an appointment today? Natalie is sharing her story in hopes that it can encourage others to prioritize preventive screenings.

The Clorox Company is dedicated to creating a culture that values and prioritizes the health and well-being of our teammates. Our benefits, programs, and resources are designed to support physical, mental and financial well-being. Learn more about life at Clorox here.

Foto: Accesswire

View additional multimedia and more ESG storytelling from The Clorox Company on 3blmedia.com.

Contact Info:
Spokesperson: The Clorox Company
Website: https://www.3blmedia.com/profiles/clorox-company
Email: [e-mail]

SOURCE: The Clorox Company

View the original press release on accesswire.com


The Clorox Stock at the time of publication of the news with a fall of -0,31 % to 127,6EUR on Tradegate stock exchange (15. Mai 2024, 15:39 Uhr).

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 124,74$, was einem Rückgang von -3,20% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Morgan Stanley

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer